|
Age (years)
|
62 (53–70)
|
|
Male gender
|
196 (66 %)
|
|
Underlying malignancies
|
|
Hematologic malignancies
|
242 (81.7 %)
|
|
Acute leukemia
|
99 (33.4 %)
|
|
Lymphoma
|
96 (32.4 %)
|
|
Multiple myeloma
|
28 (9.4 %)
|
|
Miscellaneous
|
19 (6.4 %)
|
|
Solid tumors
|
54 (18.3 %)
|
|
Uro-genital
|
17 (5.7 %)
|
|
Digestive
|
15 (5 %)
|
|
Pulmonary
|
9 (3 %)
|
|
Breast
|
6 (2 %)
|
|
Bone and cartilage
|
4 (1.3 %)
|
|
Head and neck
|
4 (1.3 %)
|
|
Hematopoietic stem cell transplantation
|
42 (14.2 %)
|
|
Other comorbidities
|
|
Chronic heart failure
|
61 (20.6 %)
|
|
Chronic liver disease
|
13 (4.4 %)
|
|
Chronic and end-stage renal failure
|
13 (4.4 %)
|
|
Human immunodeficiency virus infection
|
6 (2 %)
|
|
Solid organ transplantation
|
1 (0.3 %)
|
|
Anticoagulant and antiplatelet medications
|
69 (23.3 %)
|
|
Prophylactic anticoagulant
|
21 (7.1 %)
|
|
Curative anticoagulant
|
27 (9.1 %)
|
|
Antiplatelet
|
21 (7.1 %)
|
|
Mechanisms of central thrombocytopenia
|
|
Chemo- or radiotherapy-induced
|
223 (75.3 %)
|
|
Bone marrow infiltration by malignant cells
|
55 (18.5 %)
|
|
Hemophagocytosis
|
10 (3.4 %)
|
|
Drug-induced (allergic)
|
4 (1.3 %)
|
|
Myelofibrosis
|
4 (1.3 %)
|
